Prasun Mishra, Ph.D.

MetaImmune is a biotechnology company on the quest to find curative therapies for cancer through targeting tumor-immune interactions. Through its rich portfolio and notable partnerships, MetaImmune is pioneering innovative research, leading to the next generation of revolutionary anticancer treatments, including small molecules, biologics and immunotherapies. For more information, please visit www.metaimmune.com, follow @MetaImmune on Twitter and LinkedIn.

Agility is an artificial intelligence (AI) driven pharmaceutical company committed to revolutionizing drug discovery through BigData, Robotics and AI.

The Intramural Research Program (IRP) is the internal research program of the National Institutes of Health (NIH), known for its synergistic approach to biomedical science. With 1,200 Principal Investigators and more than 4,000 Postdoctoral Fellows conducting basic, translational, and clinical research, the IRP is the largest biomedical research institution on Earth. Its unique funding environment means the IRP can facilitate opportunities to conduct both long-term and high-impact science that would otherwise be difficult to undertake. More than 50 buildings on NIH campuses are devoted to the research enterprise, from state-of-the-art animal care facilities to homes for 7-Tesla MRIs and confocal microscopes, to a neurosciences cluster designed to foster collaborations across disciplines. Our 240-bed research hospital is devoted to clinical research protocols. With rigorous external reviews ensuring that only the most outstanding research secures funding, the IRP is responsible for many scientific accomplishments, including the discovery of fluoride to prevent tooth decay, the use of lithium to manage bipolar disorder, and the creation of vaccines against hepatitis, Haemophilus influenzae (HIB), and human papillomavirus (HPV).

The National Cancer Institute (NCI), part of the National Institutes of Health, is the lead federal agency for cancer research. For more information about NCI, visit us at www.cancer.gov. Privacy policy: https://www.cancer.gov/policies/privacy-security Engagement ≠ endorsement

The National Cancer Institute (NCI), part of the National Institutes of Health, is the lead federal agency for cancer research. For more information about NCI, visit us at www.cancer.gov. Privacy policy: https://www.cancer.gov/policies/privacy-security Engagement ≠ endorsement

GSIF is being formed with an investment objective of capital appreciation and reorientation towards sustainability through investing in companies that demonstrate their positive, global sustainable contribution as defined by the Investment Managers' binding ESG rating methodology. GSIF investment thesis focuses on the Healthcare, Energy/ Environment, Agriculture, and Education sectors that are the cornerstones of human well-being and progress. We believe that growth and development in each industry will have an unassailable spillover effect on the other three. Together, this will cause a ripple of positive changes and potentially transform life on Earth.

Headquartered in Silicon Valley, the M7 Accelerator is a healthcare innovation platform and a catalyst that provides a series of commercialization services to grow startups all over the world — a unique opportunity for entrepreneurs to build, launch and scale their big healthcare idea! ​ In M7, our mission is to link the outstanding global healthcare start-ups with investors, mentors and corporate partners, and together to build a resource-rich healthcare innovation ecosystem. We are focusing on the early-stage Biotech, MedTech and Device startups and have designed a 3-month acceleration program to fund and mentor young leaders creating the solutions for a sustainable and accessible healthcare future. ​ Need a boost with your healthcare startup? Let M7 be your support - Matter, money, mind, magnify, medicine, mentoring, master!

UC San Francisco is driven by the idea that when the best research, the best education and the best patient care converge, great breakthroughs are achieved. We pursue this integrated excellence with singular focus, fueled by collaboration among our top-ranked professional and graduate schools, medical center, research programs and support teams.

The mission of the American Association for Precision Medicine (AAPM) is to reduce adverse drug events by accelerating the field of Precision Medicine (PM) through research, education, communication, and collaboration to foster new medical breakthroughs. Through its programs and services, the AAPM fosters R&D in the PM-field and accelerates dissemination of new research findings among scientists and others dedicated to finding the right drugs, for the right patients, at the right dose, through the right route and at the right time. AAPM promotes science education and training to facilitate the ‘precision medical care’, based on an individual’s genomic, environment, and lifestyle differences enabling more precise methods to prevent and treat diseases (so that preventive or therapeutic interventions can then be concentrated on those who will benefit, sparing expense and side effects for those who will not). AAPM also facilitate a dialogue between the 4-P’ of precision medicine: Patients, providers, public health planers (Government) and payers to work together to achieve the goal of delivering improved outcomes at reduced costs.

MetaImmune is a biotechnology company on the quest to find curative therapies for cancer through targeting tumor-immune interactions. Through its rich portfolio and notable partnerships, MetaImmune is pioneering innovative research, leading to the next generation of revolutionary anticancer treatments, including small molecules, biologics and immunotherapies. For more information, please visit www.metaimmune.com, follow @MetaImmune on Twitter and LinkedIn.